论文部分内容阅读
目的:比较高剂量与常规剂量表阿霉素联合化疗方案治疗非小细胞肺癌(NSCLC)的疗效,并观察两组的毒性反应。方法:30例ⅡⅣ期非小细胞肺癌随机分成两组,每组15个病人,一组为高剂量表阿霉素组(EPI:100mg/M2),一组为常规剂量表阿霉素组(EPI:75mg/M2)。两组均采用MEP方案(MMC+EPI+DDP)治疗2周期。结果:显示高剂量、常规剂量表阿霉素组有效率(RR)分别为400%和200%。从有效率来看高剂量表阿霉素组(HDEPI组)要高于常规剂量表阿霉素组(CDEPI组),虽然两组疗效无统计学上差异(P>005)。HDEPI组发生口腔粘膜炎较多,有统计学意义(P<005),而其它毒性如胃肠道反应、骨髓抑制、静脉炎、脱发两组无显著差别(P>005),所有病例均未见明显的心脏毒性。结论:从实际值看HDEPI组疗效优于CDEPI且,而主要毒性反应两组无显著差异,值得临床推广和深入研究。
OBJECTIVE: To compare the efficacy of high-dose and conventional-dose epirubicin combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC) and to observe the toxicities of the two groups. Methods: Thirty patients with stage IIIV non-small cell lung cancer were randomly divided into two groups with 15 patients in each group. One group was a high-dose epirubicin group (EPI: 100 mg/M2) and one group was a conventional dose of epirubicin group ( EPI: 75 mg/M2). Both groups were treated with MEP regimen (MMC+EPI+DDP) for 2 cycles. RESULTS: The high-dose, routine-dose epirubicin group showed an effective rate (RR) of 400% and 200%, respectively. From the perspective of efficacy, the high-dose epirubicin group (HDEPI group) was higher than the conventional dose epirubicin group (CDEPI group), although the efficacy was not statistically different between the two groups (P>005). There was more oral mucositis in the HDEPI group (P<005), while other toxicities such as gastrointestinal reactions, myelosuppression, phlebitis, and alopecia were not significantly different (P>005). All cases were not See obvious cardiotoxicity. Conclusion: The actual value of the HDEPI group is superior to that of the CDEPI. However, there is no significant difference in the main toxicity between the two groups. It is worthy of clinical promotion and in-depth study.